2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1377

IL-22 Drives the Proliferation and Differentiation of Human Bone Marrow Mesenchymal Stem Cells (MSCs); A Novel Pathway That May Contribute to Aberrant New Bone Formation in Human Spa and Beyond
Abstract Number: 1378

AMP-Activated Protein Kinase As an Anti-Inflammatory Target for Methotrexate
Abstract Number: 1379

High Serum IgG4 Concentration Is a Risk Factor for Relapse in IgG4-Related Disease
Abstract Number: 1380

Characterization of Lymphocytes Subsets in Peripheral Blood of Untreated IgG4-Related Disease Patients
Abstract Number: 1381

The Relationship Between Serum Cholinesterase, Number of Organ Involvement and Fibrotic Markers in Japanese Patients with IgG4-Related Disease
Abstract Number: 1382

Clinical and Serum IgG4 Characteristics of a Unique British Columbian IgG4-Related Disease Cohort
Abstract Number: 1383

T-Cell Subset Analysis in IgG4-Related Disease and Lymphocyte-Variant Hypereosinophilic Syndrome
Abstract Number: 1384

Comparison of IgG4-Related and Non-IgG4-Related Retroperitoneal Fibrosis; A 12 Year Retrospective Study
Abstract Number: 1385

Efficacy and Tolerance of Rituximab in IgG4-Related Disease: A Retrospective Multicentric Study in 24 Patients
Abstract Number: 1386

Malignancy Prevalence Is Increased Among Patients before the Onset of IgG4-Related Disease
Abstract Number: 1387

Thoracic Paravertebral Masses and IgG4-Related Disease: Report of 8 Cases and Review of the Literature
Abstract Number: 1388

Adalimumab in Patients with Inactive, Non-Infectious Uveitis Requiring Systemic Treatment
Abstract Number: 1389

A Meta-Analysis of the Prevalence of the Ocular Manifestations in All Inflammatory Rheumatic Diseases
Abstract Number: 1390

Hidradenitis Suppuritiva Is Associated with Inflammatory Eye Disease
Abstract Number: 1391

Differential Expression of Interferon Gamma in Exudate from Hidradenitis Suppurativa Lesions Compared to Chronic Wounds

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].